PD ISO/TS 17822-1:2014

BSI Standards Publication

In vitro diagnostic test systems — Qualitative nucleic acid-based *in vitro* examination procedures for detection and identification of microbial pathogens

Part 1: General requirements, terms and definitions

bsi.

...making excellence a habit.™

Document Sharing Hub

Full document details: PD ISO/TS 17822-1:2014

National foreword

This Published Document is the UK implementation of ISO/TS 17822-1:2014.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2014.
Published by BSI Standards Limited 2014

ISBN 978 0 580 89200 4
ICS 01.040.19; 11.100.01

Compliance with a British Standard cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 31 December 2014.

Amendments/corrigenda issued since publication

Date	Text affected

Documents
Document Sharing Hub

Full document details: PD ISO/TS 17822-1:2014

TECHNICAL SPECIFICATION

ISO/TS 17822-1

First edition
2014-12-15

In vitro diagnostic test systems — Qualitative nucleic acid-based *in vitro* examination procedures for detection and identification of microbial pathogens —

Part 1: General requirements, terms and definitions

Systèmes d'essai pour diagnostic in vitro — Modes opératoires d'examen in vitro qualitatifs fondés sur l'acide nucléique pour la détection et l'identification d'agents pathogènes microbiens —

Partie 1: Exigences générales, termes et définitions

Reference number
ISO/TS 17822-1:2014(E)

Documents
Document Sharing Hub

© ISO 2014

Full document details: PD ISO/TS 17822-1:2014

COPYRIGHT PROTECTED DOCUMENT

© ISO 2014

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

© ISO 2014 – All rights reserved

Documents
Document Sharing Hub

Full document details: PD ISO/TS 17822-1:2014

Contents

Page

Foreword ... **iv**
Introduction ... **v**
1 Scope ... **1**
2 Normative references ... **1**
3 Terms and definitions ... **2**
4 Principles of nucleic acid based *in vitro* diagnostic examinations ... **9**
4.1 General requirements ... 9
4.1.1 Design and development ... 9
4.1.2 Implementation and use in the medical laboratory ... 10
4.2 Specimen collection, transport, and storage conditions ... 11
4.3 Selection of nucleic acid targets and sequences ... 11
4.4 Selection of primers or primer sequences ... 11
4.5 Nucleic acid preparation and stability ... 12
4.6 Nucleic acid amplification ... 12
4.7 Nucleic acid detection and identification ... 12
4.8 Reagent stability and storage conditions ... 12
5 Performance characteristics ... **13**
5.1 General requirements ... 13
5.1.1 Design and development ... 13
5.1.2 Implementation and use in the medical laboratory ... 13
5.2 Specific requirements ... 14
5.2.1 Cut-off values ... 14
5.2.2 Detection Limit ... 14
5.2.3 Analytical specificity ... 14
5.2.4 Measurement precision ... 14
5.2.5 Clinical performance ... 15
5.3 Quality control and quality assurance procedures ... 15
5.3.1 Control materials ... 15
5.3.2 Medical laboratory design and workflow ... 16
5.3.3 Medical laboratory practices ... 16
5.3.4 Commercial equipment (including software) ... 16
5.3.5 Medical laboratory personnel ... 17
5.3.6 Quality assurance procedures ... 17
5.4 Reporting of results ... 17
6 Risk management ... **17**
6.1 General ... 17
6.2 Design and development risk management ... 18
6.3 Medical laboratory risk management ... 18
Bibliography ... **20**

© ISO 2014 – All rights reserved

Documents
Document Sharing Hub
Full document details: PD ISO/TS 17822-1:2014

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT), see the following URL: Foreword — Supplementary information.

The committee responsible for this document is ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*.

ISO/TS 17822 consists of the following parts, under the general title *In vitro diagnostic test systems — Qualitative nucleic acid-based in vitro examination procedures for detection and identification of microbial pathogens*:

— *Part 1: General requirements, terms and definitions*

— *Part 2: Quality practice guide for medical laboratories*

© ISO 2014 – All rights reserved
Documents
Document Sharing Hub
Full document details: PD ISO/TS 17822-1:2014

Introduction

Nucleic acid-based *in vitro* diagnostic examination procedures are now commonly used in laboratory medicine for the detection and identification of microbial pathogens. These examination procedures have become particularly valuable for the detection of infectious agents that are difficult to grow in culture. For a review of recent advances and current practices associated with *in vitro* diagnostic examination procedures based on nucleic acid-amplification and detection technology ("molecular diagnostics"), see References [38], [35], [36], [37], [39], [41], and [42].

ISO/TS 17822-1 defines concepts and establishes general principles for the design, development, and performance of qualitative nucleic acid-based *in vitro* diagnostic examinations for the detection and identification of microbial pathogens in human specimens.

Traditional PCR examination procedures typically consist of three steps: (1) sample preparation and nucleic acid extraction, (2) nucleic acid amplification, and (3) nucleic acid detection and identification. The analytical technology is continuing to evolve. Recent kinetic approaches ("real-time PCR") incorporate detection in the amplification step, and multiplex PCR includes the entire system in a cassette.

Due to the inherent complexity and unparalleled analytical sensitivity of nucleic acid-based examination procedures, special attention to their design, development, and use is required, including determination of analytical and clinical performance characteristics, documentation of instructions for use, design of medical laboratory facilities, implementation of appropriate quality assurance practices, verification of the performance characteristics by the medical laboratory in conditions of actual use, and risk management.

As with all *in vitro* diagnostic examination procedures, suitability of a nucleic acid-based examination procedure for its intended clinical uses must be demonstrated as part of the development process. Analytical performance characteristics must be determined and validated for the detection and identification of the target pathogen. Clinical performance characteristics must be determined and validated based on clinical evidence, including evaluation of the benefits and risks to patients. Instructions for use must be clearly documented and effective quality assurance procedures must be specified.

Prior to examination of patient specimens, satisfactory implementation of the examination procedure must be verified by the medical laboratory under conditions of actual use. In other words, the successful transfer of the validated examination procedure from the development laboratory or IVD manufacturer to the end-user medical laboratory must be demonstrated by objective evidence. Any modification of the examination procedure after this transfer may require validation that the analytical and/or clinical performance remains suitable for its intended uses, including reassessment of any risks that could be affected by the modification.

© ISO 2014 – All rights reserved

Documents
Document Sharing Hub
Full document details: PD ISO/TS 17822-1:2014

Documents
Document Sharing Hub

In vitro diagnostic test systems — Qualitative nucleic acid-based *in vitro* examination procedures for detection and identification of microbial pathogens —

Part 1: General requirements, terms and definitions

1 Scope

This Technical Specification is intended for

— IVD medical device manufacturers, medical laboratories, and research and development laboratories that develop nucleic acid-based qualitative *in vitro* diagnostic examination procedures for the detection and identification of microbial pathogens in human specimens, and

— medical laboratories that perform nucleic acid-based *in vitro* diagnostic examinations for the detection and identification of microbial pathogens in human specimens.

This part of ISO/TS 17822 does not apply to

— nucleic acid-based examinations that are not intended for *in vitro* diagnostic use, or

— quantitative nucleic acid-based *in vitro* diagnostic examination procedures.

2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 13485:2003, *Medical devices — Quality management systems — Requirements for regulatory purposes*

ISO 14971:2007, *Medical devices — Application of risk management to medical devices*

ISO 15189:2012, *Medical laboratories — Requirements for quality and competence*

ISO 15190:2003, *Medical laboratories — Requirements for safety*

ISO 18113-1:2009, *In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 1: Terms, definitions and general requirements*

ISO 18113-2:2009, *In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 2: In vitro diagnostic reagents for professional use*

ISO 18113-3:2009, *In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 3: In vitro diagnostic instruments for professional use*

ISO 23640:2011, *In vitro diagnostic medical devices — Evaluation of stability of in vitro diagnostic reagents*

BIPM JCGM 200:2012, *International vocabulary of metrology — Basic and general concepts and associated terms (VIM), 3rd edition*

© ISO 2014 – All rights reserved

Documents
Document Sharing Hub

Full document details: PD ISO/TS 17822-1:2014

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 13485, ISO 14971, ISO 15189, ISO 18113-1, JCGM 200, and the following apply.

NOTE The terms and definitions given in ISO 18113-1 take precedence over other sources.

3.1
amplification product
amplicon
nucleic acid products created from a target amplification reaction

Note 1 to entry: Amplicons will be double-stranded DNA if created by a PCR reaction and will be primarily single-stranded RNA if created in a nucleic acid sequence-based amplification or transcription-mediated amplification reaction.

3.2
analytical performance
ability of an examination procedure to measure or detect a particular analyte

[SOURCE: GHTF/SG5/N 6:2012, 4.4.1, modified.]

Note 1 to entry: Analytical performance is determined from analytical performance studies used to assess the ability of an *in vitro* diagnostic examination procedure to measure or detect a particular analyte.

Note 2 to entry: Analytical performance characteristics can include analytical sensitivity, detection limit, analytical specificity (interference and cross-reactivity), trueness, precision, and linearity.

3.3
analytical specificity
capability of a measuring system, using a specified measurement procedure, to provide measurement results for one or more measurands which do not depend on each other nor on any other quantity in the system undergoing measurement

[SOURCE: ISO 18113-1:2009, A.3.4]

Note 1 to entry: Lack of analytical specificity is called analytical interference (see ISO 18113-1:2009, A.3.2).

Note 2 to entry: Lack of analytical specificity in immunochemistry measurement procedures can be due to cross-reactivity (see ISO 18113-1:2009, A.3.12).

Note 3 to entry: Specificity of a measurement procedure should not be confused with clinical specificity (see ISO 18113-1:2009, A.3.16).

Note 4 to entry: JCGM 200:2008 uses the term selectivity for this concept instead of specificity.

Note 5 to entry: For qualitative and semiquantitative examination procedures, analytical specificity is determined by the ability to obtain negative results in concordance with negative results obtained by the reference method.

3.4
annealing
process of hybridization of complementary strands of nucleic acid under specific conditions, for example, as in binding of a primer or a probe to the complementary target nucleic acid sequence

[SOURCE: ISO 22174:2005, 3.4.15]

© ISO 2014 – All rights reserved
Documents
Document Sharing Hub
Full document details: PD ISO/TS 17822-1:2014

3.5
clinical accuracy
diagnostic accuracy
(laboratory medicine) ability of an examination procedure to differentiate between patients who have a specific condition and those who do not have the condition

[SOURCE: CLSI EP29-A]

Note 1 to entry: Measures of clinical accuracy include clinical sensitivity and clinical specificity.

Note 2 to entry: Clinical accuracy is affected by the prevalence of the target disease or condition. With the same sensitivity and specificity, clinical accuracy of a particular examination procedure increases as the disease prevalence decreases.

3.6
clinical evaluation
(laboratory medicine) assessment and analysis of clinical evidence in order to verify the clinical safety and performance of an *in vitro* diagnostic examination procedure

[SOURCE: Based on GHTF/SG5/N2R8:2007]

3.7
clinical evidence
(laboratory medicine) all the information that supports the scientific validity and performance for a particular intended use

[SOURCE: GHTF/SG5/N 6:2012, 4.2, modified.]

Note 1 to entry: Clinical evidence or data can include results of any clinical investigations or studies of the *in vitro* diagnostic examination procedure, results of relevant studies reported in the scientific literature, and published or unpublished reports of other clinical experience such as adverse events.

Note 2 to entry: Clinical evidence is used to support the labelling of an IVD medical device, including any claims made about the scientific validity and performance of the device or examination procedure

3.8
clinical performance
(laboratory medicine) ability of an *in vitro* diagnostic examination procedure to yield results that are correlated with a particular clinical condition or physiological state in accordance with the target population and intended user

[SOURCE: GHTF/SG5/N 6:2012, 4.4.2, modified]

Note 1 to entry: Although sometimes referred to as diagnostic performance or clinical validity; clinical performance is the harmonized term endorsed by the Global Harmonization Task Force (GHTF) and its successor, the International Medical Device Regulators Forum (IMDRF).

Note 2 to entry: Evaluation of clinical performance often relies on the outcome of other types of clinical examinations to define “true positive or true negative” results.

3.9
clinical sensitivity
diagnostic sensitivity
(laboratory medicine) ability of an *in vitro* diagnostic examination procedure to identify the presence of a target marker associated with a particular disease or condition

[SOURCE: ISO 18113-1:2009, A.3.15]

Note 1 to entry: Also defined as percent positivity in samples where the target marker is known to be present.

© ISO 2014 – All rights reserved

Documents
Document Sharing Hub
Full document details: PD ISO/TS 17822-1:2014